Prospective Single Center Randomized Double Blind Controlled Tolerability Trial of Six Hair Cleansing Conditioners

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-04

Study Completion Date

2018-12-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hair cleansing product tolerability study

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Evaluate Skin Irritation and Skin Sensitisation of Developmental Cosmetic Facial Products

NCT04007159

Skin Care

COMPLETED NA

Repeat Insult Patch Test for Daily Advance Cetaphil Moisturizing Lotion

NCT01892423

Skin Irritation

COMPLETED NA

Dermatological Evaluation of Topical Compatibility, Primary Skin Irritability, Accumulated Skin Irritability, and Dermal Sensitisation

NCT02419248

Skin Irritability

COMPLETED

Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test

NCT01892657

Skin Irritation

COMPLETED PHASE4

Impact of Exposure to Cosmetics on Sensitive Skin

NCT03958968

Sensitive Skin Cosmetic Exposure

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Aim: The objective of this study is to evaluate the tolerability of daily use of f hair cleansing products.

Background/Study Rational/Significance: There have been consumer reports of irritancy and hair loss with use of Wen cleansing conditioner. A recent study of 142 patients found no increase in hair loss when used in normal subjects, however skin assessments for tolerability were not evaluated.

Methodology: This double-blind, randomized, controlled clinical trial will evaluate the tolerability of six hair cleansing products including Wen cleansing conditioner using two standard clinical and research methods, Repeat Open Application Tests (ROAT) (a test for irritancy) and Semi-Open Patch Tests (a test for allergenicity). For the ROAT, participants will apply the hair cleansing products to 6 separate locations on the forearm using a standardized, protocol and scored using a 10-point scale. Application site of each cleansing product will be randomized. Exposure time will be increased in a step-wise fashion over 5 weeks. Participants and investigators will be blinded to location of products. The primary outcome is intolerance; intolerance will be defined as 1) ROAT skin component scoring \>6 (of 10 maximum) or 2) ROAT global score of \>4 (of 5 maximum). If intolerance to a specific product is reached, the ROAT for that product will be discontinued. . Clinical assessments (global scoring and component scoring) will be performed at 0, 2, and 4 and 5 weeks. Primary outcomes will be measured at 5 weeks. Allergenicity is a secondary outcome and will be assessed with semi-open patch tests to the 6 hair cleansing products performed at week 4 and read at week 5

Setting/ patients: Single center study of 200 patients. To represent a broad spectrum of skin barrier function, recruitment will target enrollment of 150 individuals with a no history of childhood eczema (non-atopic) and 50 individuals with a history of childhood eczema (atopic).

Population: Men and women over the age of 18 years old.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Irritant Contact Dermatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

randomized, double-blind, controlled

Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

The six hair cleansing products will be packaged in identical 1 ml capped tuberculin syringes (with no needles) and provided to participants. Each syringe will be labeled with the forearm location for application. Identical syringes containing the six hair cleansing products will be dispensed. Treatment site allocation will be determined by a computer-generated randomization log.

Intervention Type OTHER

6 different commercially available shampoos

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Skin Testing of Hair cleansing products

6 different commercially available shampoos

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed and witnessed written informed consent
* Willingness and ability to comply with the study protocol
* For women of child-bearing potential, negative urine pregnancy test at enrollment

Exclusion Criteria

* The presence of an overt bacterial, viral or fungal infection of the arms
* The presence of any skin condition on the arms that, in the opinion of the investigator, could interfere with study assessments.
* History of bullous skin disorders, psoriasis, ichthyosis, and/or any other chronic skin condition which could result in skin barrier dysfunction (other than atopic dermatitis).
* Treatment with systemic immunosuppressive drugs within 2 weeks of enrollment.
* Treatment with topical antibacterial, antimycotic, or immunosuppressive medications (including topical corticosteroids) on the forearms within 2 weeks of enrollment.
* Use of over-the-counter moisturizers to the forearms in the 3 days prior to protocol commencement.
* Menstruating females of childbearing potential who are not willing to use a medically accepted method of contraception, during the study and up to 4 weeks after the end of study. Medically approved contraception may, at the discretion of the investigator, include abstinence.
* Women who are breastfeeding
* Patients with a severe medical condition(s) which, in the view of the investigator, prohibits participation in the study
* Use of any other investigational agent in the 30 days prior to study commencement
* Known allergy to the study products or ingredients

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes